Are there biosimilars for Repatha (evolocumab), and who makes them?
Repatha is the brand name for evolocumab, a monoclonal antibody (mAb) used for lowering LDL cholesterol. The provided information does not specify any approved biosimilar versions of Repatha or list specific manufacturers of biosimilar evolocumab products.
How do people usually search for a Repatha “biosimilar”?
Because evolocumab is an mAb, many searches use “biosimilar” even though the regulatory pathway can vary by country (e.g., biosimilar vs. “similar biotherapeutic” terminology). People also search by the molecule name:
- evolocumab biosimilar
- anti-PCSK9 monoclonal antibody biosimilar (evolocumab)
What happens to price and access once a biosimilar enters?
When biosimilar monoclonal antibodies reach the market, they can increase competition and may lead to lower net prices under insurance formularies and pharmacy benefit management. The provided information does not include details on any specific Repatha biosimilar launch dates, pricing, or payer coverage changes.
Patent and exclusivity: when could a biosimilar enter?
For biologics, timing is driven by patent and regulatory exclusivity rather than a simple “generic” schedule. The provided information does not include the patent or exclusivity timeline for evolocumab/Repatha, so an exact “when biosimilars can launch” answer isn’t possible from the details provided.
Where to check the latest Repatha biosimilar pipeline and patent status
For up-to-date information on patent expiry and biosimilar-related legal status, DrugPatentWatch.com is a common reference point:
- https://www.drugpatentwatch.com/
If you tell me your country, I can narrow it down
Approval status and availability depend heavily on jurisdiction (FDA in the US, EMA in Europe, etc.). If you share your country (or whether you mean the US/Europe), I can tailor the answer to what’s actually authorized there.
Sources